RESUMO
A 66-year-old woman was diagnosed with stage IVb sigmoid colon cancer. Modified FOLFOX-6 (mFOLFOX-6; levofolinateâfluorouracilâoxaliplatin) plus panitumumab was selected as the chemotherapeutic regimen, but she was administered a regimen without oxaliplatin (L-OHP) or bolus 5-fluorouracil (5-FU) because of her general condition and concern about adverse effects. The patient had impaired consciousness on day 3 of chemotherapy. Computed tomography (CT) and magnetic resonance imaging (MRI) of the brain showed no findings of hemorrhage, infarction, brain metastasis, and leukoencephalopathy. Except for high blood ammonia concentration (353 µg/dL), there were no other findings that could have caused her condition. Impaired consciousness due to hyperammonemia was diagnosed. We started an intravenous drip supplemented with branched chain amino acids for liver protection. Approximately 6 hours later, blood ammonia level improved to 88 µg/dL, which approached the reference value. Consciousness level improved over time, reaching a level of alertness on day 5 after starting chemotherapy. 5-FU was suspected to be the cause of impaired consciousness due to hyperammonemia, but the exact cause could not be identified because most of the previously reported cases were given L-OHP, bolus 5-FU, and other concomitant medications. In this case, since there were no other concomitant medications, it is highly probable that continuous infusion of 5-FU alone caused impaired consciousness due to hyperammonemia. This is an important case that indicates the need to monitor carefully for the occurrence of hyperammonemia when 5-FU is administered continuously; it also proposes future issues for investigation.
Assuntos
Neoplasias Colorretais , Hiperamonemia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias Colorretais/tratamento farmacológico , Estado de Consciência , Feminino , Fluoruracila/efeitos adversos , Humanos , Hiperamonemia/induzido quimicamente , Hiperamonemia/tratamento farmacológico , Leucovorina/efeitos adversosRESUMO
OBJECTIVE: This study was designed to clarify the factors affecting the efficacy, adverse events, and pharmacokinetics of fondaparinux in Japanese patients undergoing artificial knee replacement surgery. MATERIALS AND METHODS: Fondaparinux (1.5 mg/d) was administered subcutaneously to patients (n = 30) at 24 hours after surgery, and blood samples were taken at various time points thereafter. Venous thromboembolism (VTE), presence of bleeding, and pharmacokinetics were evaluated. Multivariate analysis and population pharmacokinetic analysis were performed to detect factors that necessitated withdrawal of fondaparinux and individual differences in its pharmacokinetics. RESULTS: VTE was observed in 9 patients (3 for whom administration was continued and 6 for whom withdrawal was necessary). The maximum plasma concentration of fondaparinux was found to be a significant factor determining withdrawal of the drug. Population pharmacokinetic analysis demonstrated that individual renal function and body weight were significant factors associated with apparent clearance and volume of distribution, respectively. CONCLUSIONS: A high maximum plasma concentration of fondaparinux may result in subcutaneous hemorrhage, necessitating withdrawal of fondaparinux administration. The patient's kidney function and body weight also contribute to individual differences in pharmacokinetics. We recommend considering an adjustment to the dose of fondaparinux based on body weight in patients undergoing artificial knee replacement surgery.â©.
Assuntos
Artroplastia do Joelho , Inibidores do Fator Xa/farmacocinética , Polissacarídeos/farmacologia , Polissacarídeos/farmacocinética , Idoso , Idoso de 80 Anos ou mais , Feminino , Fondaparinux , Humanos , Masculino , Pessoa de Meia-Idade , Tromboembolia Venosa/prevenção & controleRESUMO
Edoxaban was extracted from human plasma by simple protein precipitation with acetonitrile, followed by quantitative determination using a liquid chromatography-mass spectrometry method. The recoveries of edoxaban and the internal standard (ticlopidine) from human plasma were >85%, and the within- and between-day coefficients of variation were within 15%. The limit of quantification in human plasma was 1 ng/mL. The concentration of edoxaban in blood decreased at room temperature, but remained unchanged for 1 week at 4°C. On the other hand, the concentration in plasma at both -20 and -80°C remained unchanged for 5 months. These results indicated that blood samples should be centrifuged immediately or stored at 4°C, and that plasma samples should be stored below -20°C until analysis. This method was applied to human plasma obtained from four patients after total knee arthroplasty. Analysis of edoxaban pharmacokinetics demonstrated an absorption time lag of 4h, a maximum concentration of 110 ± 26 ng/mL and an oral clearance of 37 ± 16 L/h. The analytical methods established in this study will be suitable for determining the concentrations of edoxaban in human plasma.
Assuntos
Artroplastia do Joelho/efeitos adversos , Cromatografia Líquida/métodos , Inibidores do Fator Xa/sangue , Piridinas/sangue , Espectrometria de Massas em Tandem/métodos , Tiazóis/sangue , Idoso , Idoso de 80 Anos ou mais , Inibidores do Fator Xa/uso terapêutico , Feminino , Humanos , Modelos Lineares , Masculino , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/prevenção & controle , Piridinas/uso terapêutico , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Tiazóis/uso terapêutico , Tromboembolia/tratamento farmacológico , Tromboembolia/prevenção & controleRESUMO
OBJECTIVE: Timely dose reduction of concomitant medications is important after withdrawal of rifampicin, a CYP inducer. However, little is known about the differences in the time course of deinduction for various CYP isoforms. To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin. MATERIALS AND METHODS: Two patients (aged 70 and 80 years) received warfarin and rifampicin for anticoagulation and antituberculosis therapy, respectively. Warfarin doses were increased due to rifampicin-induced CYP activity. Upon completion of antituberculosis therapy, rifampicin was discontinued and warfarin doses were titrated downward according to prothrombin time. We monitored CYP2C9 and CYP3A activities over their clinical courses by measuring the metabolic clearance of S-warfarin to S-7-hydroxywarfarin and that of cortisol to 6ß-hydroxycortisol, respectively. RESULTS: In both patients, the time courses of CYP2C9 deinduction appeared to be delayed compared to CYP3A. CONCLUSION: Our findings suggest that a uniform dose reduction protocol for drugs metabolized by different CYP isoforms may be unsafe after rifampicin withdrawal.â©.
Assuntos
Antibióticos Antituberculose/efeitos adversos , Anticoagulantes/administração & dosagem , Indutores do Citocromo P-450 CYP2C9/efeitos adversos , Citocromo P-450 CYP2C9/biossíntese , Indutores do Citocromo P-450 CYP3A/efeitos adversos , Citocromo P-450 CYP3A/biossíntese , Rifampina/efeitos adversos , Varfarina/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Antibióticos Antituberculose/administração & dosagem , Anticoagulantes/efeitos adversos , Anticoagulantes/farmacocinética , Coagulação Sanguínea/efeitos dos fármacos , Indutores do Citocromo P-450 CYP2C9/administração & dosagem , Indutores do Citocromo P-450 CYP3A/administração & dosagem , Cálculos da Dosagem de Medicamento , Interações Medicamentosas , Monitoramento de Medicamentos/métodos , Indução Enzimática , Feminino , Humanos , Coeficiente Internacional Normatizado , Polimedicação , Tempo de Protrombina , Rifampina/administração & dosagem , Especificidade por Substrato , Varfarina/efeitos adversos , Varfarina/farmacocinéticaRESUMO
AIM: To clarify whether the activities of multiple CYPs associated with warfarin metabolism would be correlated with each other. METHODS: Oral clearances (CLpo) of warfarin enantiomers were estimated in 378 Chinese, Caucasians and African-Americans. The partial metabolic clearances (CLm) for 7-hydroxywarfarin enantiomers were also measured. In addition, CLpo and CLm were determined in a patient on warfarin and rifampicin. RESULTS: Correlations between CLpo for warfarin enantiomers existed across the three populations. In addition, there was a significant correlation between the CLm for 7-hydroxylation of warfarin enantiomers. Under induced conditions by rifampicin, there were significant correlations between the enantio- and regio-selective metabolisms of warfarin. CONCLUSION: Metabolic activities of CYP2C9, CYP1A2 and CYP3A4 may be regulated by common transcriptional mechanism(s).